ATYPICAL TERATOID/RHABDOID TUMOR
Clinical trials for ATYPICAL TERATOID/RHABDOID TUMOR explained in plain language.
Never miss a new study
Get alerted when new ATYPICAL TERATOID/RHABDOID TUMOR trials appear
Sign up with your email to follow new studies for ATYPICAL TERATOID/RHABDOID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail targets rare childhood cancers
Disease control OngoingThis study tests a combination of three drugs (tazemetostat, nivolumab, and ipilimumab) for children with rare tumors that lack certain proteins (INI1 or SMARCA4). The goal is to find a safe dose and see if the drugs can shrink tumors. About 49 children with specific cancers like…
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Susan Chi, MD • Aim: Disease control
Last updated May 26, 2026 06:02 UTC
-
Immunotherapy combo shows promise for Tough-to-Treat childhood tumors
Disease control OngoingThis study is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, can shrink or control rare INI1-negative cancers in children and young adults. These cancers have come back or not responded to standard treatments. The goal is to see if the drugs help the…
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 26, 2026 06:00 UTC
-
New hope for rare childhood cancers: immunotherapy combo shows promise
Disease control OngoingThis study tests two immunotherapy drugs, tiragolumab and atezolizumab, in children and adults whose rare cancers (like certain brain, kidney, and soft tissue tumors) have returned or not responded to treatment. These cancers lack specific genes (SMARCB1 or SMARCA4), making them …
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:47 UTC
-
Promising drug targets rare childhood tumors in phase 2 trial
Disease control OngoingThis study tests a drug called alisertib in children under 22 with rare, aggressive tumors of the brain (AT/RT) or kidney (MRT). For children whose cancer has returned, alisertib is given alone. For newly diagnosed children, it is combined with chemotherapy and sometimes radiatio…
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 26, 2026 05:45 UTC
-
Engineered immune cells injected directly into brain show promise for kids with cancer
Disease control OngoingThis early-stage study tests whether specially engineered immune cells (CAR T cells) can be safely given directly into the brain or spinal fluid of children and young adults with HER2-positive brain tumors that have come back or not responded to standard treatments. The cells are…
Matched conditions: ATYPICAL TERATOID/RHABDOID TUMOR
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated May 11, 2026 20:40 UTC